Common Reasons for Deficiency Notices in Overseas Medical Dressing Registration

Common reasons for deficiency notices during overseas registration of medical dressings include incorrect product classification, incomplete technical documentation, insufficient quality management system (QMS) evidence, labeling and instructions for use (IFU) that do not meet target-country requirements, inadequate clinical evaluation, and missing local agent or authorized representative arrangements. Before preparing a submission dossier, a manufacturer should first confirm whether the product falls within the scope of medical device regulation in the target country, then determine the risk class and registration pathway to avoid submitting a Class I dressing as Class II or vice versa. Additionally, systematically assess whether existing NMPA, CE, FDA, and ISO 13485 documentation can be reused, and perform a localization adaptation based on target-country regulatory requirements rather than simply translating the files.

Key Summary

Deficiency notices are not isolated technical issues but systemic gaps across classification, technical files, QMS, clinical evaluation, labeling, and local representation. For Chinese medical device manufacturers, a prudent approach is to first conduct a product classification and documentation gap assessment, then determine whether NMPA, CE, FDA, ISO 13485, or other market documentation can be reused. Target-market registration typically affects the technical dossier, authorized representative, importer coordination, label language, QMS certification, and post-market change maintenance. If a manufacturer merely focuses on 'which documents to submit' at an early stage, it is likely to face deficiency notices or rework in terms of model coverage, evidence chain consistency, label claims, and certificate control rights. AIMEILI recommends that manufacturers integrate this issue into a multi-market access strategy across GHWP member countries and use a single set of reusable core technical files to support localization for different markets, rather than rebuilding the dossier from scratch for each country.

Applicable Scenarios and Core Issues

Medical dressings are a major export category for medical devices, covering adhesive bandages, gauze, transparent dressings, hydrocolloid dressings, alginate dressings, foam dressings, and more. When applying for registration in GHWP member countries or markets in Southeast Asia, the Middle East, and Latin America, manufacturers often receive deficiency notices, causing extended registration timelines and increased costs.

The core issue is that manufacturers often directly apply their domestic registration experience or CE registration experience to the target country, ignoring the specific local regulatory requirements. For example, some countries classify dressings claiming to 'promote wound healing' as Class II or III, while the manufacturer submits as Class I, inevitably triggering a deficiency notice.

Another common problem is that manufacturers fail to maintain a complete technical file index at initial registration, making it difficult to quickly locate and supplement required evidence during a deficiency response. Responding to a deficiency notice is not simply submitting additional documents; it requires reassessing the sufficiency of evidence for product safety and performance.

Registration Decision Logic

When a deficiency notice is received, follow this logic to re-evaluate the registration strategy.

First, determine whether the product is within the target country's medical device regulatory scope. Some medical dressings may be classified as ordinary consumer products, cosmetics, or drug-device combination products. For instance, dressings containing antibacterial ingredients may be managed as drugs or combination products.

Second, determine the risk class and registration pathway. Different countries use risk-based classification rules, such as those in ASEAN, Saudi Arabia, and Brazil, which reference GHTF/IMDRF classification principles. Verify whether the product classification aligns with the target country's classification list.

Third, assess the reusability of existing documentation. If the product already holds NMPA registration, CE marking, FDA market authorization, or ISO 13485/MDSAP certification, test reports, risk management files, and clinical literature can be used as core evidence. However, check their applicability and validity.

Fourth, confirm localization requirements. Target countries may require a local agent or authorized representative, and some may also require local testing, local clinical data, or local-language labeling. Plan for localization rather than simple translation.

Documentation and Evidence

Common deficient documentation areas include the following:

• Product description and technical specifications: Clearly describe the structure, material composition, sizes, sterilization method, intended use, and contraindications. Deficiency reasons often include incomplete model coverage or inconsistencies between description and actual product.
• Performance verification data: Include physical, chemical, and microbiological performance. For example, hydrocolloid dressings require moisture absorption data, alginate dressings require gel strength data, and foam dressings require breathability data. Provide test reports that meet the target country's standards or international standards.
• Biocompatibility evaluation: Conduct cytotoxicity, sensitization, and irritation testing per ISO 10993 series. A common deficiency is that the test sample does not match the actual product or the extraction preparation procedure is not described.
• Sterilization validation and microbial barrier: For sterile dressings, provide sterilization process validation, sterility test, and shelf-life validation. Deficiencies often arise from missing sterilization dose setting and re-sterilization instructions.
• Risk management documentation: Establish risk management files per ISO 14971. Common deficiencies include incomplete risk analysis, failure to consider clinical use risks, or lack of evidence for effectiveness of risk control measures.
• Clinical evaluation: For Class II and above dressings, clinical literature, clinical experience, or clinical trial data may be required. Provide a systematic clinical evaluation report.
• Labeling and instructions for use: Must comply with target-country language requirements and include correct symbols, warnings, and storage conditions. Deficiencies often result from missing local agent information or use of a non-official language.

Common Mistakes

• Misjudgment of product classification: Submitting a Class II dressing as Class I, or failing to consider combination product / drug-device cross-regulation.
• Copying other market dossiers: Directly translating CE technical files into the target language without adjusting format and content to local requirements.
• Over-reliance on non-clinical testing: Ignoring the representativeness of biocompatibility test samples or using testing laboratory qualifications not recognized by the target country.
• Mismatched QMS documentation: ISO 13485 certificate covers a different manufacturing site than the registration application, or lacks specific required QMS elements.
• Label and IFU translation errors: Non-standard terminology, incorrect measurement units, or missing warning statements required by local regulations.
• Underestimating the local agent role: Not appointing an authorized representative, or the agent's qualifications are non-compliant or the scope of authorization is unclear.
• Lack of post-market surveillance plan: No post-market vigilance and adverse event reporting procedure, or no person designated to update the application.

Enterprise Preparation Checklist

• Confirm regulatory boundary in the target country: Determine whether the product is a medical device and identify the competent authority and legal basis.
• Complete risk classification assessment: Determine the risk class and registration category according to target-country classification rules.
• Establish a core technical file library: Manage basic information such as product description, drawings, material composition, and intended use.
• Organize performance test reports: Physical, chemical, microbiological, biocompatibility, etc., ensuring reports are valid and complete.
• Prepare risk management documentation: Update risk analysis, risk evaluation, and risk control measures per ISO 14971.
• Prepare sterilization validation data: Provide sterilization method, parameters, validation report, and sterilization confirmation records.
• Create labeling and IFU: Translate into target-country language and include all mandatory labeling items.
• Appoint a local agent: Sign an authorization agreement clarifying the agent's duties in registration, post-market surveillance, and vigilance events.

AIMEILI Viewpoint

Many manufacturers mistakenly believe overseas registration is simply 'translation plus notarization'—in fact, every country has unique technical review priorities. We recommend performing a 'gap analysis' before project initiation, comparing the existing dossier item-by-item against target-country requirements to identify what can be reused, what requires additional testing, and what must be created from scratch. This approach significantly reduces the number of deficiency notices.

The most critical early step is to clarify product classification and registration pathway; otherwise, all subsequent work may be overturned. Consult a regulatory advisor with local experience as early as possible.

Regarding document reuse, animal testing, biocompatibility, and sterilization validation data from NMPA registrations, CE technical files, or FDA 510(k) submissions can be partially reused, but you must confirm whether the target country recognizes these test standards. Some countries require biocompatibility testing in local or designated laboratories.

Local agent and certificate control rights are easily overlooked issues. Many registration certificates are held by local agents; if the agent is changed or fails to cooperate, the certificate may become invalid or unable to be updated or renewed. Therefore, we recommend clarifying certificate ownership and operational rights in the contract to ensure the manufacturer has practical control.

For multi-country registration, we recommend a structured approach of 'core documentation + country-specific difference files'. This way, when multiple countries issue deficiency notices simultaneously, you can address only the country-specific differences, avoiding repeated reproduction of the entire dossier and reducing compliance risks from version confusion.

Frequently Asked Questions

How long does a deficiency response typically take?

The timeline depends on the complexity of the deficiencies and the manufacturer's response speed. Simple items, such as label modifications, may be completed within one month; however, if additional biocompatibility testing or sterilization validation is required, it may take three to six months or longer. Manufacturers should establish an internal rapid-response mechanism and allow sufficient review time.

Is approval guaranteed after responding to deficiency notices?

No. Responding is part of the review process. If the revised submission still fails to meet regulatory requirements, the application may be rejected. Manufacturers should fully understand the deficiency comments and resolve all issues in a single, thorough response to avoid repeated deficiencies.

Can a third party handle deficiency responses on behalf of the manufacturer?

Yes. Professional local regulatory consulting companies or overseas registration agents typically have extensive experience in responding to deficiencies. However, the manufacturer must ensure its own technical team can provide the necessary technical data and clearly define the communication scope and confidentiality terms with the third party.

Source: Compiled based on the AIMEILI registration practice database, medical device international registration knowledge base, and public regulatory information. Published on August 29, 2026, 19:22; updated on August 29, 2026, 19:22. Specific projects should be based on the latest requirements of the target-country regulatory authority and the product documentation basis.